ДИСЛИПИДЕМИИ И ИХ АССОЦИАЦИИ С ХРОНИЧЕСКИМИ НЕИНФЕКЦИОННЫМИ ЗАБОЛЕВАНИЯМИ (ИССЛЕДОВАНИЕ МЕРИДИАН-РО)

Abstract

Objective: to study the frequency of lipid disorders and their association with chronic non-communicable diseases (NCD) in the unorganized population of Ryazan’ region 25–64 yo. Materials and methods. The study was conducted as a prospective cohort with a cross-sectional retrospective and included the study of biochemical samples, an electrocardiogram and a survey using a standardized questionnaire. In a study in 1622 people were included in 2011 (1220 – city, 402 – rural) in the 25–64 years of age (mean age – 43.4 ± 11.4 years), of which, 42.6 % were male, 53.8 % – female. The cohort was observed 36 months, annually evaluated endpoints. Dyslipidemia was considered as total cholesterol greater than 5 mmol/L and/or low density lipoprotein more than 2.5 mmol/L. Results. The prevalence of dyslipidemia in the population of the Ryazan region was 84.1 % (81.4 % – the city, 89.3 % – the village, p = 0.0001). It was found that an increase in apolipoprotein B, more than 180 mg/dL was associated with an increased risk of more than 5 % on the SCORE (OR 1.81, 95 % CI 1.61–2.03), diabetes (OR 1.87, 95 % CI 1,38–2,54), hypertension (OR 1.44, 95 % CI 1.29–1.60), CKD (OR 1.83, 95 % CI 1.28–2.62), gastrointestinal diseases (OR 1.12, 95 % CI 1.02–1.24), and ischemic heart disease/stroke/myocardial infarction combined point (ОR 1.61, 95 % CI 1.05–2.46). Increased total cholesterol greater than 5 mmol/L or low-density lipoprotein cholesterol greater than 2.5 mmol/L was also associated with hypertension (OR 1.28, 95 % CI 1.08–1.51), CKD (OR 1.97, 95 % CI 1.04–3.71) and dorsopathy. Links with ischemic heart disease/stroke/myocardial infarction has been received (ОR 0.89, 95 % CI 0.51– 1.56). Ups increased the risk of death from all causes (RR 3.98, 95 % CI 1.48–10.70, p = 0.006) and the combined endpoint (RR 7.12, 95 % CI 3.26–15.57, p = 0.0001). Conclusion. The frequency of dyslipidemia in the Ryazan’ region was high and amounted to 84.1 %. Adverse outcomes of NCD associated with elevated levels of apoB in the MERIDIAN-RO study, which should be considered when assessing the atherogenic dyslipidemia.